Abstract
A new method of reduction of autoimmune process activity related to the thyroid in patients without signs of thyroiditis is presented in the article (patent of Ukraine No. 103742). New patents and inventions from different countries of the world related to the problem have been analysed. Materials and Methods: Sixty one patients with a significant disturbance of tolerance to the thyroid antigens in the absence of disturbance of the thyroid function were involved in the research. Twenty two patients with chronic hepatitis C, genotype 1 HCV, receiving antiviral therapy, were also included in the research. Patients were immunized intracutaneously with autoleukocytes for autoimmune process inhibition. After single immunization with autoleukocytes decrease in the level of antibodies against the thyroid antigens was observed in all patients. In some patients without chronic hepatitis C the levels of thyroperoxidase and thyroglobulin antibodies decreased by 50% and more (33.33% and 20.51%, respectively). In patients with ChHC these indices were considerably lower, and the duration of the achieved effect was shorter. However, immunization inhibited activity of immune process in patients with ChHC due to interferon therapy. The suggested method enables to decrease the threat for thyroiditis development even in patients with chronic hepatitis C during antiviral therapy.
Keywords: Autoimmune process, autoleukocytes, immunization, thyroid autoantibodies, thyroglobulin antibodies, thyroperoxidase.
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued)
Title:Reduction of Hyperproduction of Thyroid Autoantibodies in Patients without Disturbance of the Thyroid Function: New Patents
Volume: 8 Issue: 2
Author(s): Borys A. Gerasun, Olga A. Holubovska, Roman Y. Hrytsko, Olexandr N. Zinchuk and Andrij V. Shkurba
Affiliation:
Keywords: Autoimmune process, autoleukocytes, immunization, thyroid autoantibodies, thyroglobulin antibodies, thyroperoxidase.
Abstract: A new method of reduction of autoimmune process activity related to the thyroid in patients without signs of thyroiditis is presented in the article (patent of Ukraine No. 103742). New patents and inventions from different countries of the world related to the problem have been analysed. Materials and Methods: Sixty one patients with a significant disturbance of tolerance to the thyroid antigens in the absence of disturbance of the thyroid function were involved in the research. Twenty two patients with chronic hepatitis C, genotype 1 HCV, receiving antiviral therapy, were also included in the research. Patients were immunized intracutaneously with autoleukocytes for autoimmune process inhibition. After single immunization with autoleukocytes decrease in the level of antibodies against the thyroid antigens was observed in all patients. In some patients without chronic hepatitis C the levels of thyroperoxidase and thyroglobulin antibodies decreased by 50% and more (33.33% and 20.51%, respectively). In patients with ChHC these indices were considerably lower, and the duration of the achieved effect was shorter. However, immunization inhibited activity of immune process in patients with ChHC due to interferon therapy. The suggested method enables to decrease the threat for thyroiditis development even in patients with chronic hepatitis C during antiviral therapy.
Export Options
About this article
Cite this article as:
Gerasun A. Borys, Holubovska A. Olga, Hrytsko Y. Roman, Zinchuk N. Olexandr and Shkurba V. Andrij, Reduction of Hyperproduction of Thyroid Autoantibodies in Patients without Disturbance of the Thyroid Function: New Patents, Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) 2014; 8 (2) . https://dx.doi.org/10.2174/1872214808666140604144552
DOI https://dx.doi.org/10.2174/1872214808666140604144552 |
Print ISSN 1872-2148 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3334 |
Related Articles
-
Acute Hemorrhagic Edema of Infancy: A Diagnostic Challenge for the General Pediatrician
Current Pediatric Reviews Pathobiology of Stent Thrombosis after Drug-Eluting Stent Implantation
Current Pharmaceutical Design Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Inhibitors in the Treatment of Hypercholesterolemia and other Pathologies
Current Pharmaceutical Design Cardiovascular Effects of Modulators of Soluble Guanylyl Cyclase Activity
Cardiovascular & Hematological Agents in Medicinal Chemistry MDMA Administration and Heat Shock Proteins Response: Foreseeing a Molecular Link
Current Pharmaceutical Biotechnology Update on the Molecular Genetic Studies of Behcets Disease
Current Rheumatology Reviews New Therapies in SLE
Recent Patents on Inflammation & Allergy Drug Discovery A Simple and Rapid Method for Expression and Purification of Functional TNF-α Using GST Fusion System
Current Pharmaceutical Biotechnology Effects of N-Acetyl-L-Cysteine and Hyaluronic Acid on HBOC-201- Induced Systemic and Cerebral Vasoconstriction in the Rat
Current Drug Discovery Technologies Multiple Faceted Roles of Cocaine in Potentiation of HAND
Current HIV Research Flunarizine Dihydrochloride Nanoemulsion for Migraine Nasal Drug Delivery: Fabrication, Characterization and In Vitro Study
Drug Delivery Letters Platelets in Rheumatic Diseases: Friend or Foe?
Current Pharmaceutical Design The Influence of Different Disease States on Rituximab Pharmacokinetics
Current Drug Metabolism Lymphoid-Specific Tyrosine Phosphatase (Lyp): A Potential Drug Target For Treatment of Autoimmune Diseases
Current Drug Targets Anti-CD20 in Targeting B Lymphocytes for the Treatment of Autoimmune Diseases: Clinical Benefits and Insights into the Role of B Lymphocytes in Pathophysiology
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Targeted Delivery for Neurodegenerative Disorders Using Gene Therapy Vectors: Gene Next Therapeutic Goals
Current Gene Therapy Hendra and Nipah Viruses: Pathogenesis and Therapeutics
Current Molecular Medicine Pathologic Findings of Autoimmune Pancreatitis and IgG4-Related Disease
Current Immunology Reviews (Discontinued) Hypersensitivity to Lamotrigine and Nonaromatic Anticonvulsant Drugs: A Review
Current Pharmaceutical Design The Blood-Brain Barrier: Its Influence in the Treatment of Brain Tumors Metastases
Current Cancer Drug Targets